{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:00:19Z","timestamp":1772276419504,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":49,"publisher":"Springer US","isbn-type":[{"value":"9781071642559","type":"print"},{"value":"9781071642566","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4256-6_2","type":"book-chapter","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T15:08:23Z","timestamp":1732547303000},"page":"25-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Marburg Virus Medical Countermeasures"],"prefix":"10.1007","author":[{"given":"Karen A.","family":"Martins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel N.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"2_CR1","unstructured":"CDC (2023) Marburg virus disease outbreaks. 2023 [cited 2023 8\/22\/2023]. Available from: https:\/\/www.cdc.gov\/vhf\/marburg\/outbreaks\/chronology.html"},{"issue":"1","key":"2_CR2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41467-020-14327-8","volume":"11","author":"BR Amman","year":"2020","unstructured":"Amman BR, Bird BH, Bakarr IA, Bangura J, Schuh AJ et al (2020) Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa. Nat Commun 11(1):510","journal-title":"Nat Commun"},{"issue":"7","key":"2_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000536","volume":"5","author":"JS Towner","year":"2009","unstructured":"Towner JS, Amman BR, Sealy TK, Reeder Carroll SA, Comer JA et al (2009) Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 5(7):e1000536","journal-title":"PLoS Pathog"},{"issue":"12","key":"2_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3390\/v10120683","volume":"10","author":"BG Schindell","year":"2018","unstructured":"Schindell BG, Webb AL, Kindrachuk J (2018) Persistence and sexual transmission of filoviruses. Viruses 10(12):683","journal-title":"Viruses"},{"key":"2_CR5","doi-asserted-by":"publisher","first-page":"P505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M et al (2017) Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet 389:P505\u2013P518","journal-title":"Lancet"},{"key":"2_CR6","unstructured":"FDA (2023) Package Insert \u2013 ERVEBO. 2023 [cited 2023 8\/21\/2023]. Available from: https:\/\/www.fda.gov\/media\/133748\/download#:~:text=ERVEBO%C2%AE%20is%20indicated%20for,months%20of%20age%20and%20older.&text=The%20duration%20of%20protection%20conferred%20by%20ERVEBO%20is%20unknown.,-%E2%80%A2&text=ERVEBO%20does%20not%20protect%20against%20other%20species%20of%20Ebolavirus%20or%20Marburgvirus.,-%E2%80%A2"},{"issue":"10","key":"2_CR7","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","volume":"78","author":"M Garbutt","year":"2004","unstructured":"Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V, Klenk H, Feldmann H, Stroher U (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78(10):5458\u20135465","journal-title":"J Virol"},{"key":"2_CR8","unstructured":"NIAID (2021) NIAID pandemic preparedness plan. www.niaid.nih.gov\/research\/pandemic-preparedness"},{"key":"2_CR9","unstructured":"BARDA (2022) BARDA\u2019s strategic plan 2022\u20132026. 2022 [cited 2023 8\/21\/2023]. Available from: https:\/\/medicalcountermeasures.gov\/barda\/strategic-plan\/"},{"key":"2_CR10","unstructured":"whitehouse.gov (2022) National Biodefense Strategy and Implementation Plan, W. House, Editor"},{"key":"2_CR11","volume":"351","author":"consortium, E.c.s.r.v.t","year":"2015","unstructured":"consortium, E.c.s.r.v.t (2015) The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ 351:h3740","journal-title":"BMJ"},{"issue":"8","key":"2_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm7108a2","volume":"71","author":"JH Malenfant","year":"2021","unstructured":"Malenfant JH, Joyce A, Choi MJ, Cossaboom CM, Whitesell AN et al (2021) Use of Ebola vaccine: expansion of recommendations of the Advisory Committee on immunization practices to include two additional populations\u2014United States, 2021. MMWR Morb Mortal Wkly Rep 71(8):290\u2013292","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2_CR13","unstructured":"WHO (2023) WHO Technical Advisory Group \u2013 candidate vaccine prioritization. www.who.int\/publications\/m\/item\/marburg-virus-vaccine-landscape"},{"key":"2_CR14","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M et al (2019) A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381:2293\u20132303","journal-title":"N Engl J Med"},{"issue":"574","key":"2_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/pgmj.49.574.542","volume":"49","author":"GA Martini","year":"1973","unstructured":"Martini GA (1973) Marburg virus disease. Postgrad Med J 49(574):542\u2013546","journal-title":"Postgrad Med J"},{"issue":"3","key":"2_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.chom.2018.08.003","volume":"24","author":"KM Coffin","year":"2018","unstructured":"Coffin KM, Liu J, Warren TK, Blancett CD, Kuehl KA et al (2018) Persistent Marburg virus infection in the testes of nonhuman primate survivors. Cell Host Microbe 24(3):405\u2013416.e3","journal-title":"Cell Host Microbe"},{"key":"2_CR17","unstructured":"BARDA (2023) BARDA Target Product Profiles (TPP). 2023 [cited 2023 8\/24\/2023]. Available from: https:\/\/medicalcountermeasures.gov\/barda\/tpp"},{"key":"2_CR18","unstructured":"NIAID (2023) Target Product Profile (TPP) for APP antiviral therapeutics: Filovirus disease. 2023 [cited 2023 8\/24\/2023]. Available from: https:\/\/www.niaid.nih.gov\/sites\/default\/files\/filovirus-target-product-antivirals.pdf"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","volume":"377","author":"SB Kennedy","year":"2017","unstructured":"Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M et al (2017) Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 377:1438\u20131447","journal-title":"N Engl J Med"},{"issue":"675","key":"2_CR20","doi-asserted-by":"publisher","first-page":"eabq6364","DOI":"10.1126\/scitranslmed.abq6364","volume":"14","author":"R Hunegnaw","year":"2022","unstructured":"Hunegnaw R, Honko AN, Wang L, Carr D, Murray T et al (2022) A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. Sci Transl Med 14(675):eabq6364","journal-title":"Sci Transl Med"},{"issue":"11","key":"2_CR21","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3390\/vaccines10111935","volume":"10","author":"CL Finch","year":"2022","unstructured":"Finch CL, King TH, Alfson KJ, Albanese KA, Smith JN et al (2022) Single-shot ChAd3-MARV vaccine in modified formulation buffer shows 100% protection of NHPs. Vaccines (Basel) 10(11):1935","journal-title":"Vaccines (Basel)"},{"issue":"10373","key":"2_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","volume":"401","author":"MJ Hamer","year":"2023","unstructured":"Hamer MJ, Houser KV, Hofstetter AR, Ortega-Villa AM, Lee C et al (2023) Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet 401(10373):294\u2013302","journal-title":"Lancet"},{"issue":"6","key":"2_CR23","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/vaccines11061120","volume":"11","author":"LA Parish","year":"2023","unstructured":"Parish LA, Stavale EJ, Houchens CR, Wolfe DN (2023) Developing vaccines to improve preparedness for filovirus outbreaks: the perspective of the USA Biomedical Advanced Research and Development Authority (BARDA). Vaccine 11(6):1120","journal-title":"Vaccine"},{"key":"2_CR24","unstructured":"mcm.gov (2023) BARDA continues partnership with Sabin Vaccine Institute to advance development and manufacturing of two filovirus vaccines. medicalcountermeasures.gov"},{"issue":"10269","key":"2_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx L, Folegatti PM et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99\u2013111","journal-title":"Lancet"},{"issue":"2","key":"2_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/vaccines8020241","volume":"8","author":"S Sebastian","year":"2020","unstructured":"Sebastian S, Flaxman A, Cha KM, Ulaszewska M, Gilbride C et al (2020) A multi-filovirus vaccine candidate: co-expression of Ebola, Sudan, and Marburg antigens in a single vector. Vaccine (Basel) 8(2):241","journal-title":"Vaccine (Basel)"},{"key":"2_CR27","unstructured":"Oxford, U.o (2023) Overview of ChAdOx1 Marburg. 2023 [cited 2023 8\/24\/2023]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/teresa-lambe_session-1_university-of-oxford-_marvac-consultation_10-march-2023.pdf?sfvrsn=f68c9e1e_3"},{"issue":"10","key":"2_CR28","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/vaccines10101582","volume":"10","author":"CL Cooper","year":"2022","unstructured":"Cooper CL, Morrow G, Yuan M, Coleman JW, Hou F et al (2022) Vaccination with a vesicular stomatitis virus vector-based vaccine prepared under conditions to allow advancement to human clinical trials. Vaccine 10(10):1582","journal-title":"Vaccine"},{"issue":"7","key":"2_CR29","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/vaccines10071004","volume":"10","author":"W Zhu","year":"2022","unstructured":"Zhu W, Liu G, Cao W, He S, Leung A et al (2022) A cloned recombinant vesicular stomatitis virus-vectored Marburg vaccine, PHV01, protects Guinea pigs from lethal Marburg virus disease. Vaccines (Basel) 10(7):1004","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"2_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","volume":"20","author":"DK Clarke","year":"2020","unstructured":"Clarke DK, Rong X, Matassov D, Latham TE, Ota-Setlik A et al (2020) Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis 20(4):455\u2013466","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2_CR31","doi-asserted-by":"publisher","first-page":"e01190","DOI":"10.1128\/JVI.01190-17","volume":"92","author":"D Matassov","year":"2018","unstructured":"Matassov D, Mire CE, Latham T, Geisbert JB, Xu R et al (2018) Single-dose trivalent vesiculovax vaccine protects macaques from lethal ebolavirus and Marburgvirus challenge. J Virol 92(3):e01190\u2013e01117","journal-title":"J Virol"},{"issue":"5","key":"2_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010433","volume":"16","author":"C Woolsey","year":"2022","unstructured":"Woolsey C, Cross RW, Agans KN, Borisevich V, Deer DJ et al (2022) A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl Trop Dis 16(5):e0010433","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"2_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274906","volume":"17","author":"V Bockstal","year":"2022","unstructured":"Bockstal V, Shukarev G, McLean C, Goldsstein N, Bart S et al (2022) First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: a randomized, controlled study. PLoS One 17(10):e0274906","journal-title":"PLoS One"},{"issue":"8","key":"2_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/vaccines10081263","volume":"10","author":"MM Tiemessen","year":"2022","unstructured":"Tiemessen MM, Solforosi L, Dekking L, Czapska-Casey D, Serroyen J et al (2022) Protection against Marburg virus and Sudan virus in NHP by an adenovector-based trivalent vaccine regimen is correlated to humoral immune response levels. Vaccine (Basel) 10(8):1263","journal-title":"Vaccine (Basel)"},{"issue":"6","key":"2_CR35","doi-asserted-by":"publisher","first-page":"e01865","DOI":"10.1128\/JVI.01865-18","volume":"93","author":"R Keshwara","year":"2019","unstructured":"Keshwara R, Hagen KR, Abreu-Mota T, Papaneri AB, Liu D et al (2019) A recombinant rabies virus expressing the Marburg virus glycoprotein is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model. J Virol 93(6):e01865\u2013e01818","journal-title":"J Virol"},{"issue":"Suppl 7","key":"2_CR36","doi-asserted-by":"publisher","first-page":"S648","DOI":"10.1093\/infdis\/jiad266","volume":"228","author":"DC Malherbe","year":"2023","unstructured":"Malherbe DC, Brian Kimble J, Atyeo C, Fischinger S, Meyer M et al (2023) A single dose intranasal combination panebolavirus vaccine. J Infect Dis 228(Suppl 7):S648\u2013S659","journal-title":"J Infect Dis"},{"key":"2_CR37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/infdis\/jiu511","volume":"211","author":"UN Sarwar","year":"2014","unstructured":"Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z et al (2014) Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase 1 clinical trial. J Infect Dis 211:549\u2013557","journal-title":"J Infect Dis"},{"issue":"3","key":"2_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/v13030382","volume":"13","author":"J Jiang","year":"2021","unstructured":"Jiang J, Ramos SJ, Bangalore P, Elwood D, Cashman KA et al (2021) Multivalent DNA vaccines as a strategy to combat multiple concurrent epidemics: mosquito-borne and hemorrhagic fever viruses. Viruses 13(3):382","journal-title":"Viruses"},{"key":"2_CR39","unstructured":"United STates Department of Defense (2020) DOD-funded drug remdesivir receives FDA approval for COVID-19 treatment. 2020 [cited 2023 11\/19\/2023]. Available from: https:\/\/www.jpeocbrnd.osd.mil\/Media\/News\/Article\/2431405\/dod-funded-drug-remdesivir-receives-fda-approval-for-covid-19-treatment\/"},{"key":"2_CR40","doi-asserted-by":"crossref","unstructured":"FDA (2020) FDA approves first treatment for COVID-19. 2020 [cited 2023 11\/19\/2023]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19","DOI":"10.1038\/d41573-020-00025-z"},{"issue":"3","key":"2_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010220","volume":"16","author":"MR Hickman","year":"2022","unstructured":"Hickman MR, Saunders DL, Bigger CA, Kane CD, Iversen PL (2022) The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. PLoS Negl Trop Dis 16(3):e0010220","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"2_CR42","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/infdis\/jiaa290","volume":"222","author":"BP Porter","year":"2020","unstructured":"Porter BP, Weidner JM, Gomba L, Bannister R, Blair C et al (2020) Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with Marburg virus. J Infect Dis 222(11):1894\u20131901","journal-title":"J Infect Dis"},{"issue":"1","key":"2_CR43","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s41467-021-22132-0","volume":"12","author":"RW Cross","year":"2021","unstructured":"Cross RW, Bornholdt ZA, Prasad AN, Borisevich V, Agans KN et al (2021) Combination therapy protects macaques against advanced Marburg virus disease. Nat Commun 12(1):1891","journal-title":"Nat Commun"},{"issue":"1","key":"2_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","volume":"23","author":"LB King","year":"2018","unstructured":"King LB, Fusco ML, Flyak AI, Ilinykh PA, Huang K et al (2018) The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. Cell Host Microbe 23(1):101\u2013109.e4","journal-title":"Cell Host Microbe"},{"issue":"384","key":"2_CR45","doi-asserted-by":"publisher","first-page":"eaai8711","DOI":"10.1126\/scitranslmed.aai8711","volume":"9","author":"CE Mire","year":"2017","unstructured":"Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN et al (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9(384):eaai8711","journal-title":"Sci Transl Med"},{"issue":"6","key":"2_CR46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrd.2017.251","volume":"17","author":"RW Cross","year":"2018","unstructured":"Cross RW, Mire CE, Feldmann H, Geisbert TW (2018) Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discov 17(6):413\u2013434","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"2_CR47","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/vaccines10081213","volume":"10","author":"I Crozier","year":"2022","unstructured":"Crozier I, Britson KA, Wolfe DN, Klena JD, Hensley LE et al (2022) The evolution of medical countermeasures for Ebola virus disease: lessons learned and next steps. Vaccine (Basel) 10(8):1213","journal-title":"Vaccine (Basel)"},{"key":"2_CR48","unstructured":"FDA (2015) Product development under the animal rule guidance for industry. 2015 [cited 2023 9\/1\/2023]. Available from: https:\/\/www.fda.gov\/media\/88625\/download"},{"issue":"10","key":"2_CR49","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3390\/v14102291","volume":"14","author":"JE Comer","year":"2022","unstructured":"Comer JE, Brasel T, Massey S, Beasley DW, Cirimotich CM et al (2022) Natural history of Marburg virus infection to suppor medical countermeasure development. Viruses 14(10):2291","journal-title":"Viruses"}],"container-title":["Methods in Molecular Biology","Marburg Virus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4256-6_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T16:05:00Z","timestamp":1732550700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4256-6_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"ISBN":["9781071642559","9781071642566"],"references-count":49,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4256-6_2","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"26 November 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}